Author

Number of items: 31.
Article
  • ‘Great ease and simplicity of action’: Dr Nelson’s Inhaler and the origins of modern inhalation therapy. (2017) Barry Murnane, Darragh Murnane, Mark Sanders and Noel Snell
  • A personalized medicine approach to the design of dry powder inhalers: : Selecting the optimal amount of bypass. (2017) Thomas Kopsch, Darragh Murnane and Digby Symons
  • Dispersing the Mists: An Experimental History of Medicine Study into the Quality of Volatile Inhalations. (2017) Barry Murnane, Cathal Gallagher, Noel Snell, Mark Sanders, Ramin Moshksar and Darragh Murnane
  • Predicting the Fine Particle Fraction of Dry Powder Inhalers Using Artificial Neural Networks. (2017) Joanna Muddle, Stewart B. Kirton, Irene Parisini, Andrew Muddle, Darragh Murnane, Jogoth Ali, Marc Brown, Clive Page and Ben Forbes
  • Optimizing the Entrainment Geometry of a Dry Powder Inhaler : Methodology and Preliminary Results. (2016) Thomas Kopsch, Darragh Murnane and Digby Symons
  • Establishing the importance of oil-membrane interactions on the transmembrane diffusion of physicochemically diverse compounds. (2016) Omaima N. Najib, Gary P Martin, Stewart Kirton, Al-Sayed Sallam and Darragh Murnane
  • Mathematical approach for understanding deagglomeration behaviour of drug powder in formulations with coarse carrier. (2015) Irene Parisini, James L. Collett and Darragh Murnane
  • Interaction of Formulation and Device Factors Determine the In Vitro Performance of Salbutamol Sulphate Dry Powders for Inhalation. (2015) Joanna Muddle, Darragh Murnane, Irene Parisini, Marc Brown, Clive Page and Ben Forbes
  • Direct Ionization of Solid-Phase Microextraction Fibers for Quantitative Drug Bionalysis : From Peripheral Circulation to Mass Spectrometry Detection. (2015) Ahmad, Sheelan, Tucker, Michael, Spooner, Neil, Darragh Murnane and Ute Gerhard
  • Formulation pre-screening of inhalation powders using computational atom-atom systematic search method. (2015) Vasuki Ramachandran, Darragh Murnane, Robert B. Hammond, Jonathan Pickering, Kevin J. Roberts, Majeed Soufian, Ben Forbes, Sara Jaffari, Gary P. Martin, Elizabeth Collins and Klimentina Pencheva
  • Evidence for the existence of powder sub-populations in micronized materials : Aerodynamic size-fractions of aerosolized powders possess distinct physicochemical properties. (2014) Sara Jaffari, Ben Forbes, Elizabeth Collins, Jiyi Khoo, Gary P. Martin and Darragh Murnane
  • Potential of a cyclone prototype spacer to improve in vitro dry powder delivery. (2014) Irene Parisini, Sean J Cheng, Digby Symons and Darragh Murnane
  • Dynamics of aerosol size during inhalation : Hygroscopic growth of commercial nebulizer formulations. (2014) Allen E. Haddrell, James F. Davies, Rachael E. H. Miles, Jonathan P. Reid, Lea Ann Dailey and Darragh Murnane
  • Rapid characterisation of the inherent dispersibility of respirable powders using dry dispersion laser diffraction. (2013) Sara Jaffari, Ben Forbes, Elizabeth Collins, David J. Barlow, Gary P. Martin and Darragh Murnane
  • Nitrogen-14 Nuclear Quadrupole Resonance Spectroscopy: : a powerful new analytical methodology for medicines authentication and counterfeit antimalarial analysis. (2013) Jamie Barras, Darragh Murnane, Kaspar Althoefer, Sulaf Assi, MIchael D. Rowe, Iain J. F. Poplett, Georgia Kyriakidou and John A. S. Smith
  • Concordance, adherence or competence – device use and therapeutic outcomes in older patients. (2013) Darragh Murnane
  • Formation and measurement of process induced disorder during the manufacture of inhalation medicines. (2011) P.G. Royall, B. Woodhead, S.J. Tang, G.P. Martin, B.M. Stockton and D. Murnane
  • Characterization of latent heat-releasing phase change materials for dermal therapies. (2011) D.G. Wood, Marc Brown, S. A. Jones and D. Murnane
  • Dry Powder Formulations for Inhalation of Fluticasone Propionate and Salmeterol Xinafoate Microcrystals. (2009) Darragh Murnane, Gary P. Martin and Christopher Marriott
  • Investigations into the formulation of metered dose inhalers of salmeterol xinafoate and fluticasone propionate microcrystals. (2008) Darragh Murnane, Gary P. Martin and Christopher Marriott
  • Polymorphic control of inhalation microparticles prepared by crystallization. (2008) Darragh Murnane, Christopher Marriott and Gary P. Martin
  • In situ and Ex situ analysis of salmeterol xinafoate microcrystal formation from poly(ethylene glycol) 400 - Water cosolvent mixtures. (2008) Darragh Murnane, Christopher Marriott and Gary P. Martin
  • Comparison of salmeterol xinafoate microparticle production by conventional and novel antisolvent crystallization. (2008) Darragh Murnane, Christopher Marriott and Gary P. Martin
  • Developing an environmentally benign process for the production of microparticles : Amphiphilic crystallization. (2008) Darragh Murnane, Christopher Marriott and Gary P. Martin
  • Validation of a reverse-phase high performance liquid chromatographic method for concurrent assay of a weak base (salmeterol xinafoate) and a pharmacologically active steroid (fluticasone propionate). (2006) D Murnane, G P Martin and C Marriott
  • Other
  • Assessment of a cyclone-type spacer device for use in dry powder inhalation. (2013) I. Parisini, S. J. Cheng, D. D. Symons, Marc Brown, A. Kostrzewski and D. Murnane
  • The effect of aerodynamic particle size and solid state disorder on salmeterol xinafoate deposition from pressurised metered dose and dry powder inhaler formulations. (2013) S. Jaffari, G. Sandhu, G. P. Martin, B. Forbes, E. Collins and D. Murnane
  • Transiently supersaturated solutions from the dissolution of amorphous powders for topical drug delivery. (2010) I. A. Palmer, S. A. Jones, D. Murnane, M.J. Traynor, Gary Moss and Marc Brown
  • Evidence for flocculation-controlled microcrystallisation of salmeterol xinafoate. (2006) D. Murnane, G.P. Martin, I. Haley and C. Marriott
  • Particle aggregation of salmeterol xinafoate (SX) in HFA134a high pressure suspensions. (2006) D. Murnane, G.P. Martin and C. Marriott
  • Investigation of a reverse-phase high performance liquid chromatography (RP-HPLC) method for a weakly basic drug. (2005) D. Murnane, G. P. Martin and C. Marriott